• Overactive bladder (OAB) is a relatively common condition, with symptoms affecting up to 35.6% of men and women >40 years of age (1).
• In the treatment of OAB, mirabegron and onabotulinumtoxinA have both been found to be efficacious relative to standard-of-care therapies, although they have not been compared head-tohead.
• Limitations to published network meta-analyses (NMAs) comparing mirabegron to onabotulinumtoxinA include the following:
• No limits imposed regarding prior treatment experience, which has led to heterogeneous evidence informing the comparison of interest;
• Mirabegron (and antimuscarinics) studies have been typically conducted in a mixed patient population of treatment-naïve and treatment-experienced patients; and • OnabotulinumtoxinA studies have been conducted in treatment-experienced patients only (with longer disease history and greater disease severity).
• No analysis of safety endpoints; and • No consideration of potential differences in placebo response associated with the different types of placebo (oral vs injection).
BACKGROUND Population
Adult individuals diagnosed with OAB (defined as idiopathic overactive bladder, or idiopathic urge urinary incontinence, or non-neurogenic urge urinary incontinence, or refractory detrusor over activity, with/without urinary incontinence) who have received at least one other prior OAB pharmacotherapy
Interventions/ Comparators
Intervention:
• Mirabegron (25 and 50 mg)
• OnabotulinumtoxinA (100 U) Comparators:
• 
RESULTS

SLR & post-hoc analyses (Figure 1)
• In total, 19 studies described in 21 publications were included in the NMA; ten studies assessed mirabegron and six studies assessed onabotulinumtoxinA. No study directly compared mirabegron with onabotulinumtoxinA.
• Fifteen eligible publications describing results from 13 studies among treatment-experienced patients were identified in the SLR.
• Six mirabegron studies originally excluded from the SLR were included in the NMA via post-hoc analyses.
• Patient characteristics
• Patients were predominantly female, with the proportion ranging from 59.8% to 90.2% in mirabegron study arms and 80.0% to 93.1% in onabotulinumtoxinA study arms.
• The proportion of patients who were ≥65 years of age varied between the two treatment groups; ranging from 17.1% to 100.0% in mirabegron study arms compared to 42.6% to 53.1% in onabotulinumtoxinA study arms.
• Type of OAB (i.e. urge urinary incontinence, frequency and mixed) was not reported across onabotulinumtoxinA studies. Across mirabegron studies, urge urinary incontinence was the most common OAB type reported, making up to 33.3% to 61.0% of OAB patients.
NMA (Figure 2)
• Efficacy • OnabotulinumtoxinA was weakly associated with superior efficacy relative to mirabegron (50 mg) at reducing the number of micturitions in a 24-hour period (-0.43; credible interval [Crl]: -1.22, 0.37). No evidence of differing placebo responses was identified, therefore a SA was conducted where a common placebo was assumed in the network (-0.64; CrI: -1.01, -0.26).
• OnabotulinumtoxinA was weakly associated with better efficacy at reducing the number of incontinence episodes (-0.46; CrI: -1.46, 0.53). There was evidence of differing placebo responses across placebos for this endpoint, therefore a SA assuming a common placebo was not conducted.
• Mirabegron was estimated to be similarly efficacious to onabotulinumtoxinA at reducing nocturia episodes (0.03; Crl: -0.30, 0.38). No evidence of differing placebo responses was identified, therefore a SA was conducted where a common placebo was assumed in the network (-0.05; CrI: -0.23, 0.13).
• Safety • OnabotulinumtoxinA was associated with greater odds of UTI relative to mirabegron 50 mg (OR = 2.97, Crl: 0.87, 10.21). No evidence of differing placebo responses was identified, therefore a SA was conducted where a common placebo was assumed in the network (OR = 3.10, CrI: 1.61, 5.88).
• There was insufficient evidence to establish relative safety for all other outcomes.
• Urinary retention was sufficiently reported across included studies. Between 6 and 16 cases reported urinary retention across onabotulinumtoxinA studies. However, as none of the patients treated with mirabegron experienced the outcome, the OR could not be estimated.
OBJECTIVE
The objective of this study was to estimate the efficacy and safety of mirabegron relative to onabotulinumtoxinA in the management of patients with OAB who have been previously treated with antimuscarinics.
METHODS
Systematic literature review (SLR) & post-hoc analysis
• SLR was conducted using Medline, EMBASE, Cochrane library, and PubMed, and was guided by the PICOS criteria presented in Table 1 . The review focused on treatments and doses approved in the United States for the management of OAB.
• For a study to be included in the SLR, at least 80% of the study participants were required to have previously received pharmacotherapy for the management of their OAB, or have results reported for the subgroup of treatment-experienced patients.
• For mirabegron studies, individual patient data were available, and a post-hoc analysis of the treatment-experienced subgroup was conducted for those studies that failed to meet the minimum inclusion criterion of 80% treatment-experienced patients, and this evidence was considered in the NMA.
Feasibility assessment
• A feasibility assessment was conducted to determine which study endpoints could be included in the NMA based on available evidence. Criteria included:
• Existence of a network that connected mirabegron to onabotulinumtoxinA;
• Consistency in the evidence base with respect to study patient populations; and • Consistency in endpoint definitions.
NMA
• Treatments with sufficient evidence for inclusion in the NMA included:
• Mirabegron (25 and 50 mg/day);
• OnabotulinumtoxinA (100U);
• Solifenacin (5, 10 mg/day);
• Oxybutynin chloride (10 mg /day);
• Tolterodine extended release (ER) (4 mg/day); and • Placebo (oral, injection, and mix [i.e. oral + injection]).
• The base case network differentiated between placebo injection, placebo oral, and placebo mix to test for differences in placebo response.
• For endpoints where there was no strong evidence noted for different placebo responses, a sensitivity analysis (SA) was conducted, where placebos were pooled into a common placebo, simplifying the network and reducing the number of parameters being estimated.
• The full NMA network structure based on evidence identified in the SLR is presented in Figure 1 .
• Node-splitting was conducted to assess the consistency between direct and indirect evidence.
• All analyses were conducted in R version 3.4.0 and package R2WinBUGS version 2.1-12. All analyses followed recommendations for evidence synthesis set forth by the National Institute for Health and Care Excellence Decision Support Unit.
LIMITATIONS CONCLUSIONS
• In a treatment-experienced OAB population, relative to mirabegron, onabotulinumtoxinA is more efficacious at reducing the number of daily micturitions, with an estimated 0.64 fewer micturitions per 24 hours.
• OnabotulinumtoxinA is also associated with a three-fold greater odds of UTIs compared to mirabegron.
• Urinary retention was identified as a safety outcome in onabotulinumtoxinA studies; however, due to statistical limitations, relative safety for this endpoint between onabotulinumtoxinA and mirabegron could not be quantified.
• This study contributes to the body of evidence regarding treatment for OAB:
• This is the first study known to focus on a treatment-experienced patient population, to investigate relative safety between onabotulinumtoxinA and mirabegron 50 mg, as well as the first study to address placebo differences.
• Post-hoc analysis of mirabegron studies on treatment-experienced patients had the potential to affect study randomization.
• Thorough checks were conducted to compare estimates of treatment effect based on the full study population to estimates based on the subset of treatment-experienced patients.
• Overall, estimates aligned with those reported in the original studies, suggesting that no major impacts to randomization effects were present.
• As with all NMAs, this NMA is subject to risk of bias by including evidence from studies with low quality.
• However, the quality of the available evidence was assessed using the framework of the GRADE Working Group, and all identified studies were determined to be of moderate or high quality. 
